Looking Off-Label: Drug-Eluting Stents Versus Surgery And Bare-Metal
This article was originally published in The Gray Sheet
Two registry studies reported last week assess outcomes from drug-eluting stent procedures in patients with conditions that are not approved indications for the device. In one, the stents did not match the outcomes of open-heart surgery, but in the other the devices outpeformed their bare-metal cousins
You may also be interested in...
U.S. drug-eluting-stent market penetration reached an all-time low in September, but clinicians meeting last week in Washington, D.C., are confident new data will help to reverse the trend that began just over a year ago
FDA panel members recommended changes to drug-eluting stent labeling that would more clearly indicate differences between on- and off-label use. However, they found that the data was insufficient to make definitive conclusions about risks for unapproved applications, which account for the majority of stent placements
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.